Therma Bright (TBRIF)
OTHER OTC:TBRIF
Want to see TBRIF full AI Analyst Report?
TBRIF Stock Chart & Stats
$0.04
<$0.01(2.88%)
At close: 4:00 PM EST
$0.04
<$0.01(2.88%)
Day’s Range― - ―
52-Week Range$0.03 - $0.18
Previous CloseN/A
Volume100.00
Average Volume (3M)4.36K
Market Cap
$2.77M
Enterprise Value$3.51M
Total Cash (Recent Filing)$36.19K
Total Debt (Recent Filing)$40.00K
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Jul 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding58,002,876
10 Day Avg. Volume395
30 Day Avg. Volume4,359
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.51
Price to Sales (P/S)48.92
P/FCF Ratio-26.80
Enterprise Value/Market Cap1.27
Enterprise Value/Revenue52.10
Enterprise Value/Gross Profit235.64
Enterprise Value/Ebitda-0.90
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Reported DebtVery low reported debt (~40k) limits near-term leverage and interest obligations, preserving flexibility. Over the next several months this reduces immediate financing pressure, lowers bankruptcy risk, and gives management time to pursue partnerships or equity raises before leverage becomes a constraint.
Improving Operating Cash FlowMaterial improvement in TTM operating cash flow demonstrates tighter cost control and operational discipline versus prior years. If sustained, the smaller negative cash outflow extends runway, reduces near-term external funding needs, and increases the probability of reaching breakeven or achieving strategic milestones.
Strategic Focus On Diagnostics & Point-of-CareTherma Bright’s focus on diagnostic and point-of-care devices targets structurally growing healthcare needs and recurring testing demand. This positioning supports durable product-market fit, potential for consumable-driven recurring revenue, and makes the business attractive for long-term partnerships or licensing.
Bears Say
Negative Shareholders' EquityMeaningful negative equity reflects accumulated losses and weakens the balance sheet. Negative equity limits access to non-dilutive capital, can impair supplier and partner confidence, and restricts strategic options; reversing this requires sustained profit improvement or fresh capital injections.
Persistent Cash BurnDespite recent improvement, ongoing negative free cash flow (~-126k TTM) means the company cannot self-fund growth. Persistent cash burn necessitates continued external financing, risks dilution, and constrains investments in commercial scale-up or R&D, limiting durable operational progress without new capital.
Volatile, Declining Revenue And Deep LossesTTM revenue decline (~-10% vs prior annual) combined with very large negative margins (~-59%) signals weak demand visibility and an unclear path to profitability. Structural recovery requires consistent revenue stabilization and margin expansion, which remain uncertain given current trends.
Therma Bright News
TBRIF FAQ
What was Therma Bright’s price range in the past 12 months?
Therma Bright lowest stock price was $0.03 and its highest was $0.18 in the past 12 months.
What is Therma Bright’s market cap?
Therma Bright’s market cap is $2.77M.
When is Therma Bright’s upcoming earnings report date?
Therma Bright’s upcoming earnings report date is Jul 01, 2026 which is in 56 days.
How were Therma Bright’s earnings last quarter?
Therma Bright released its earnings results on Apr 07, 2026. The company reported -$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.004.
Is Therma Bright overvalued?
According to Wall Street analysts Therma Bright’s price is currently Overvalued.
Does Therma Bright pay dividends?
Therma Bright does not currently pay dividends.
What is Therma Bright’s EPS estimate?
Therma Bright’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Therma Bright have?
Therma Bright has 58,002,876 shares outstanding.
What happened to Therma Bright’s price movement after its last earnings report?
Therma Bright reported an EPS of -$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.511%.
Which hedge fund is a major shareholder of Therma Bright?
Currently, no hedge funds are holding shares in TBRIF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Therma Bright
Therma Bright Inc. engages in the development and sale of rapid COVID testing products, medical devices for pain management, devices to improve circulation, and devices for the cosmeceutical industry. The company's products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. It serves consumers and medical professionals. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.
Technical Analysis
Imagin Medical
―
Perimeter Medical Imaging AI
―
Profound Medical
―
Theralase Technologies
―
Aquarius Surgical Technologies
―
Ownership Overview
Options Prices
Currently, No data available
---